The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: A trial of the University of Chicago phase II consortium

Halla S. Nimeiri, Deepti A. Singh, Kristen Kasza, David A. Taber, Rafat H. Ansari, Everett E. Vokes, Hedy L. Kindler

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Purpose Hepatobiliary cancers respond poorly to cytotoxic chemotherapy. We evaluated the activity and safety of ixabepilone, an epothilone B analogue which stabilizes microtubules, in a phase II trial in patients with advanced cancers of the gallbladder, bile duct, and liver. Methods Eligible patients had previously-untreated, histologically-proven unresectable hepatobiliary cancer. Ixabepilone, 40 mg/m2, was administered intravenously over 3 h every 21 days. Results Between January 2002 and April 2005, 54 patients (19 hepatocelluar carcinoma, 13 cholangiocarcinomas, 22 gallbladder carcinomas) were enrolled; 47 patients were evaluable for efficacy. The objective response rate was 8.5%; 51% had stable disease. Median overall survival was 7.0 months (95% CI, 5.0 to 10.8 months) and median progression-free survival was 2.6 months (95% CI, 1.4 to 4.1 months). Grade 3/4 toxicities included neutropenia (39%), fatigue (9%), allergic/hypersensitivity reaction (4%) and sensory neuropathy (4%). Conclusion Single agent ixabepilone has limited activity in advanced hepatobiliary cancers.

Original languageEnglish (US)
Pages (from-to)854-858
Number of pages5
JournalInvestigational New Drugs
Volume28
Issue number6
DOIs
StatePublished - Dec 2010

Keywords

  • Epothilone
  • Hepatobiliary cancers

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: A trial of the University of Chicago phase II consortium'. Together they form a unique fingerprint.

Cite this